Androgen deprivation therapy (ADT) for the treatment of prostate cancer may be associated with an increased risk for dementia, according to a study published in JAMA Oncology.1
Researchers led by Kevin Nead, MD, MPhil, of Stanford University School of Medicine in California conducted a cohort study of 9272 men with prostate cancer who were analyzed for their electronic medical record data using a text-processing method.
The study’s authors tested for the potential risk of dementia from ADT through propensity score-matched Cox proportional hazards regression models and Kaplan-Meier survival analysis.
Continue Reading
The researchers found a statistically significant association between ADT use and risk for dementia, with similar results when excluding patients with Alzheimer disease upon sensitivity analyses.
RELATED: Ipilimumab Fails to Improve Overall Survival in mCR Prostate Cancer
Absolute increased risk for developing dementia among patients who received ADT was 4.4% at 5 years, and individuals with at least 12 months of ADT use had the greatest absolute increased risk for dementia upon stratification by duration of ADT.
Patients undergoing ADT who were 70 years or older had the highest cumulative probability of developing dementia, according to Kaplan-Meier analysis.
Reference
- Nead KT, Gaskin G, Chester C, et al. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2016 Oct 13. doi:10.1001/jamaoncol.2016.3662 [Epub ahead of print]
